Testing dapagliflozin for septic shock with poor blood flow
Part of Infections clinical trials.
This trial tests whether a diabetes drug called dapagliflozin can help repair damaged small blood vessels in patients with septic shock. It is for people recently diagnosed with septic shock who have signs of poor blood flow to the skin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have been diagnosed with septic shock (a severe infection causing low blood pressure) within the last 12 hours
- You have mottled skin (patchy discoloration) or a slow blood return to skin after pressure (more than 3 seconds)
- You are not on kidney dialysis
- You are not pregnant or breastfeeding
- You are not already taking a similar medication (SGLT2 inhibitor) for diabetes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether empagliflozin, a diabetes medicine, helps improve blood flow in tiny blood vessels for people in cardiogenic shock. If it helps, it could improve recovery for people with this serious heart condition.
This trial tests whether a diabetes medicine called dapagliflozin can help reduce inflammation in people with sepsis (a serious infection). If you are in the ICU with sepsis, this drug may improve your recovery.
This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
This trial tests if dapagliflozin, a medication usually used for diabetes, can help people with acute heart failure recover heart function. If you are in the hospital for heart failure, this study will check if the drug improves how your heart squeezes.
Hear when a new Septic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.